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ABSTRACT 
Curcumin, a bioactive compound in Curcuma longa, exhibits various pharmacological 
activities, including antimalarial effects. In silico docking simulation studies suggest that 
curcumin possesses glycogen synthase kinase-3β (GSK3β)-inhibitory properties. The 
involvement of GSK3 in the antimalarial effects in vivo is yet to be demonstrated. In this 
study, we aimed to evaluate whether the antimalarial effects of curcumin involve 
phosphorylation of host GSK3β. Intraperitoneal administration of curcumin into Plasmodium 
berghei NK65-infected mice resulted in dose-dependent chemosuppression of parasitemia 
development. At the highest dose tested (30 mg/kg body weight), both therapeutic and 
prophylactic administrations of curcumin resulted in suppression exceeding 50% and 
improved median survival time of infected mice compared to control. Western analysis 
revealed a 5.5-fold (therapeutic group) and 1.8-fold (prophylactic group) increase in 
phosphorylation of Ser 9 GSK3β and 1.6-fold (therapeutic group) and 1.7-fold (prophylactic 
group) increase in Ser 473 Akt in liver of curcumin-treated infected animals. Following P. 
berghei infection, levels of pro- and anti-inflammatory cytokines, tumor necrosis factor 
(TNF)-α, interferon (IFN)-γ, interleukin (IL)-10, and IL-4 were elevated by 7.5-, 35.0-, 33.0-, 
and 2.2-fold, respectively. Curcumin treatment (therapeutic) caused a significant decrease (by 
6.0- and 2.0-fold, respectively) in serum TNF-α and IFN-γ level, while IL-10 and IL-4 were 
elevated (by 1.4- and 1.8-fold). Findings from the present study demonstrate for the first time 
that the antimalarial action of curcumin involved inhibition of GSK3β. 
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